Cargando…
Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas
MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226002/ https://www.ncbi.nlm.nih.gov/pubmed/32260556 http://dx.doi.org/10.3390/cancers12040884 |
_version_ | 1783534185385820160 |
---|---|
author | Vazquez, Ivonne Papaleo, Natalia Garcia, Eugenia Salido, Marta Salar, Antonio Hernandez, Silvia Calvo, Xavier Colomo, Luis |
author_facet | Vazquez, Ivonne Papaleo, Natalia Garcia, Eugenia Salido, Marta Salar, Antonio Hernandez, Silvia Calvo, Xavier Colomo, Luis |
author_sort | Vazquez, Ivonne |
collection | PubMed |
description | MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas. |
format | Online Article Text |
id | pubmed-7226002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72260022020-05-18 Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas Vazquez, Ivonne Papaleo, Natalia Garcia, Eugenia Salido, Marta Salar, Antonio Hernandez, Silvia Calvo, Xavier Colomo, Luis Cancers (Basel) Article MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas. MDPI 2020-04-05 /pmc/articles/PMC7226002/ /pubmed/32260556 http://dx.doi.org/10.3390/cancers12040884 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vazquez, Ivonne Papaleo, Natalia Garcia, Eugenia Salido, Marta Salar, Antonio Hernandez, Silvia Calvo, Xavier Colomo, Luis Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
title | Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
title_full | Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
title_fullStr | Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
title_full_unstemmed | Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
title_short | Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas |
title_sort | clinical interest of lmo2 testing for the diagnosis of aggressive large b-cell lymphomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226002/ https://www.ncbi.nlm.nih.gov/pubmed/32260556 http://dx.doi.org/10.3390/cancers12040884 |
work_keys_str_mv | AT vazquezivonne clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT papaleonatalia clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT garciaeugenia clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT salidomarta clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT salarantonio clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT hernandezsilvia clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT calvoxavier clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas AT colomoluis clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas |